VBI Vaccines Inc.
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vacci… Read more
VBI Vaccines Inc. (VBIVQ) - Total Assets
Latest total assets as of March 2024: $75.44 Million USD
Based on the latest financial reports, VBI Vaccines Inc. (VBIVQ) holds total assets worth $75.44 Million USD as of March 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
VBI Vaccines Inc. - Total Assets Trend (2020–2023)
This chart illustrates how VBI Vaccines Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
VBI Vaccines Inc. - Asset Composition Analysis
Current Asset Composition (December 2023)
VBI Vaccines Inc.'s total assets of $75.44 Million consist of 41.7% current assets and 58.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $8.50 Million | 9.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $36.50 Million | 42.0% |
| Goodwill | $1.13 Million | 1.3% |
Asset Composition Trend (2020–2023)
This chart illustrates how VBI Vaccines Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VBI Vaccines Inc.'s current assets represent 41.7% of total assets in 2023, a decrease from 63.1% in 2020.
- Cash Position: Cash and equivalents constituted 27.2% of total assets in 2023, down from 44.8% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 42.0% of total assets, an increase from 30.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 42.0% of total assets.
VBI Vaccines Inc. Competitors by Total Assets
Key competitors of VBI Vaccines Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
VBI Vaccines Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - VBI Vaccines Inc. generates 0.10x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - VBI Vaccines Inc. is currently not profitable relative to its asset base.
VBI Vaccines Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.34 | 1.75 | 1.75 |
| Quick Ratio | 0.21 | 1.52 | 1.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-51.23 Million | $ 22.26 Million | $ 22.26 Million |
VBI Vaccines Inc. - Advanced Valuation Insights
This section examines the relationship between VBI Vaccines Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -43.9% |
| Total Assets | $86.95 Million |
| Market Capitalization | $4.75 USD |
Valuation Analysis
Below Book Valuation: The market values VBI Vaccines Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: VBI Vaccines Inc.'s assets decreased by 43.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for VBI Vaccines Inc. (2020–2023)
The table below shows the annual total assets of VBI Vaccines Inc. from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $86.95 Million | -43.93% |
| 2022-12-31 | $155.09 Million | -26.25% |
| 2021-12-31 | $210.28 Million | +0.43% |
| 2020-12-31 | $209.37 Million | -- |